Biomimetic polymeric transcatheter heart valve leaflets with low calcification and good regenerative ability

Transcatheter aortic valve replacement (TAVR) technology is quickly advancing in clinic, however, as it expands to low-risk populations and younger patients (age <65 years), device durability is becoming a major challenge.